NeuPSIG guidelines on neuropathic pain assessment

Maija Haanpää, Nadine Attal, Miroslav Backonja, Ralf Baron, Michael Bennett, Didier Bouhassira, Giorgio Cruccu, Per Hansson, Jennifer Haythornthwaite, Gian Domenico Iannetti, Troels S. Jensen, Timo Kauppila, Turo J. Nurmikko, Andew S C Rice, Michael Rowbotham, Jordi Serra, Claudia Sommer, Blair H. Smith, Rolf Detlef Treede

Research output: Contribution to journalArticle

Abstract

This is a revision of guidelines, originally published in 2004, for the assessment of patients with neuropathic pain. Neuropathic pain is defined as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system either at peripheral or central level. Screening questionnaires are suitable for identifying potential patients with neuropathic pain, but further validation of them is needed for epidemiological purposes. Clinical examination, including accurate sensory examination, is the basis of neuropathic pain diagnosis. For more accurate sensory profiling, quantitative sensory testing is recommended for selected cases in clinic, including the diagnosis of small fiber neuropathies and for research purposes. Measurement of trigeminal reflexes mediated by A-beta fibers can be used to differentiate symptomatic trigeminal neuralgia from classical trigeminal neuralgia. Measurement of laser-evoked potentials is useful for assessing function of the A-delta fiber pathways in patients with neuropathic pain. Functional brain imaging is not currently useful for individual patients in clinical practice, but is an interesting research tool. Skin biopsy to measure the intraepidermal nerve fiber density should be performed in patients with clinical signs of small fiber dysfunction. The intensity of pain and treatment effect (both in clinic and trials) should be assessed with numerical rating scale or visual analog scale. For future neuropathic pain trials, pain relief scales, patient and clinician global impression of change, the proportion of responders (50% and 30% pain relief), validated neuropathic pain quality measures and assessment of sleep, mood, functional capacity and quality of life are recommended.

Original languageEnglish (US)
Pages (from-to)14-27
Number of pages14
JournalPain
Volume152
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Neuralgia
Pain Measurement
Guidelines
Pain
Trigeminal Neuralgia
Functional Neuroimaging
Visual Analog Scale
Nerve Fibers
Research
Reflex
Sleep
Quality of Life
Biopsy
Skin

Keywords

  • Assessment
  • Autonomic nervous system
  • Clinical examination
  • Disability
  • Epidemiology
  • Evoked potentials
  • Functional brain imaging
  • Microneurography
  • Neuropathic pain
  • Pain intensity
  • Pain measurement
  • Pain quality
  • Psychological assessment
  • Quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Neurology
  • Pharmacology

Cite this

Haanpää, M., Attal, N., Backonja, M., Baron, R., Bennett, M., Bouhassira, D., ... Treede, R. D. (2011). NeuPSIG guidelines on neuropathic pain assessment. Pain, 152(1), 14-27. https://doi.org/10.1016/j.pain.2010.07.031

NeuPSIG guidelines on neuropathic pain assessment. / Haanpää, Maija; Attal, Nadine; Backonja, Miroslav; Baron, Ralf; Bennett, Michael; Bouhassira, Didier; Cruccu, Giorgio; Hansson, Per; Haythornthwaite, Jennifer; Iannetti, Gian Domenico; Jensen, Troels S.; Kauppila, Timo; Nurmikko, Turo J.; Rice, Andew S C; Rowbotham, Michael; Serra, Jordi; Sommer, Claudia; Smith, Blair H.; Treede, Rolf Detlef.

In: Pain, Vol. 152, No. 1, 01.2011, p. 14-27.

Research output: Contribution to journalArticle

Haanpää, M, Attal, N, Backonja, M, Baron, R, Bennett, M, Bouhassira, D, Cruccu, G, Hansson, P, Haythornthwaite, J, Iannetti, GD, Jensen, TS, Kauppila, T, Nurmikko, TJ, Rice, ASC, Rowbotham, M, Serra, J, Sommer, C, Smith, BH & Treede, RD 2011, 'NeuPSIG guidelines on neuropathic pain assessment', Pain, vol. 152, no. 1, pp. 14-27. https://doi.org/10.1016/j.pain.2010.07.031
Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011 Jan;152(1):14-27. https://doi.org/10.1016/j.pain.2010.07.031
Haanpää, Maija ; Attal, Nadine ; Backonja, Miroslav ; Baron, Ralf ; Bennett, Michael ; Bouhassira, Didier ; Cruccu, Giorgio ; Hansson, Per ; Haythornthwaite, Jennifer ; Iannetti, Gian Domenico ; Jensen, Troels S. ; Kauppila, Timo ; Nurmikko, Turo J. ; Rice, Andew S C ; Rowbotham, Michael ; Serra, Jordi ; Sommer, Claudia ; Smith, Blair H. ; Treede, Rolf Detlef. / NeuPSIG guidelines on neuropathic pain assessment. In: Pain. 2011 ; Vol. 152, No. 1. pp. 14-27.
@article{548a70cbe5ff4020be1d0f6eeb35ad18,
title = "NeuPSIG guidelines on neuropathic pain assessment",
abstract = "This is a revision of guidelines, originally published in 2004, for the assessment of patients with neuropathic pain. Neuropathic pain is defined as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system either at peripheral or central level. Screening questionnaires are suitable for identifying potential patients with neuropathic pain, but further validation of them is needed for epidemiological purposes. Clinical examination, including accurate sensory examination, is the basis of neuropathic pain diagnosis. For more accurate sensory profiling, quantitative sensory testing is recommended for selected cases in clinic, including the diagnosis of small fiber neuropathies and for research purposes. Measurement of trigeminal reflexes mediated by A-beta fibers can be used to differentiate symptomatic trigeminal neuralgia from classical trigeminal neuralgia. Measurement of laser-evoked potentials is useful for assessing function of the A-delta fiber pathways in patients with neuropathic pain. Functional brain imaging is not currently useful for individual patients in clinical practice, but is an interesting research tool. Skin biopsy to measure the intraepidermal nerve fiber density should be performed in patients with clinical signs of small fiber dysfunction. The intensity of pain and treatment effect (both in clinic and trials) should be assessed with numerical rating scale or visual analog scale. For future neuropathic pain trials, pain relief scales, patient and clinician global impression of change, the proportion of responders (50{\%} and 30{\%} pain relief), validated neuropathic pain quality measures and assessment of sleep, mood, functional capacity and quality of life are recommended.",
keywords = "Assessment, Autonomic nervous system, Clinical examination, Disability, Epidemiology, Evoked potentials, Functional brain imaging, Microneurography, Neuropathic pain, Pain intensity, Pain measurement, Pain quality, Psychological assessment, Quality of life",
author = "Maija Haanp{\"a}{\"a} and Nadine Attal and Miroslav Backonja and Ralf Baron and Michael Bennett and Didier Bouhassira and Giorgio Cruccu and Per Hansson and Jennifer Haythornthwaite and Iannetti, {Gian Domenico} and Jensen, {Troels S.} and Timo Kauppila and Nurmikko, {Turo J.} and Rice, {Andew S C} and Michael Rowbotham and Jordi Serra and Claudia Sommer and Smith, {Blair H.} and Treede, {Rolf Detlef}",
year = "2011",
month = "1",
doi = "10.1016/j.pain.2010.07.031",
language = "English (US)",
volume = "152",
pages = "14--27",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - NeuPSIG guidelines on neuropathic pain assessment

AU - Haanpää, Maija

AU - Attal, Nadine

AU - Backonja, Miroslav

AU - Baron, Ralf

AU - Bennett, Michael

AU - Bouhassira, Didier

AU - Cruccu, Giorgio

AU - Hansson, Per

AU - Haythornthwaite, Jennifer

AU - Iannetti, Gian Domenico

AU - Jensen, Troels S.

AU - Kauppila, Timo

AU - Nurmikko, Turo J.

AU - Rice, Andew S C

AU - Rowbotham, Michael

AU - Serra, Jordi

AU - Sommer, Claudia

AU - Smith, Blair H.

AU - Treede, Rolf Detlef

PY - 2011/1

Y1 - 2011/1

N2 - This is a revision of guidelines, originally published in 2004, for the assessment of patients with neuropathic pain. Neuropathic pain is defined as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system either at peripheral or central level. Screening questionnaires are suitable for identifying potential patients with neuropathic pain, but further validation of them is needed for epidemiological purposes. Clinical examination, including accurate sensory examination, is the basis of neuropathic pain diagnosis. For more accurate sensory profiling, quantitative sensory testing is recommended for selected cases in clinic, including the diagnosis of small fiber neuropathies and for research purposes. Measurement of trigeminal reflexes mediated by A-beta fibers can be used to differentiate symptomatic trigeminal neuralgia from classical trigeminal neuralgia. Measurement of laser-evoked potentials is useful for assessing function of the A-delta fiber pathways in patients with neuropathic pain. Functional brain imaging is not currently useful for individual patients in clinical practice, but is an interesting research tool. Skin biopsy to measure the intraepidermal nerve fiber density should be performed in patients with clinical signs of small fiber dysfunction. The intensity of pain and treatment effect (both in clinic and trials) should be assessed with numerical rating scale or visual analog scale. For future neuropathic pain trials, pain relief scales, patient and clinician global impression of change, the proportion of responders (50% and 30% pain relief), validated neuropathic pain quality measures and assessment of sleep, mood, functional capacity and quality of life are recommended.

AB - This is a revision of guidelines, originally published in 2004, for the assessment of patients with neuropathic pain. Neuropathic pain is defined as pain arising as a direct consequence of a lesion or disease affecting the somatosensory system either at peripheral or central level. Screening questionnaires are suitable for identifying potential patients with neuropathic pain, but further validation of them is needed for epidemiological purposes. Clinical examination, including accurate sensory examination, is the basis of neuropathic pain diagnosis. For more accurate sensory profiling, quantitative sensory testing is recommended for selected cases in clinic, including the diagnosis of small fiber neuropathies and for research purposes. Measurement of trigeminal reflexes mediated by A-beta fibers can be used to differentiate symptomatic trigeminal neuralgia from classical trigeminal neuralgia. Measurement of laser-evoked potentials is useful for assessing function of the A-delta fiber pathways in patients with neuropathic pain. Functional brain imaging is not currently useful for individual patients in clinical practice, but is an interesting research tool. Skin biopsy to measure the intraepidermal nerve fiber density should be performed in patients with clinical signs of small fiber dysfunction. The intensity of pain and treatment effect (both in clinic and trials) should be assessed with numerical rating scale or visual analog scale. For future neuropathic pain trials, pain relief scales, patient and clinician global impression of change, the proportion of responders (50% and 30% pain relief), validated neuropathic pain quality measures and assessment of sleep, mood, functional capacity and quality of life are recommended.

KW - Assessment

KW - Autonomic nervous system

KW - Clinical examination

KW - Disability

KW - Epidemiology

KW - Evoked potentials

KW - Functional brain imaging

KW - Microneurography

KW - Neuropathic pain

KW - Pain intensity

KW - Pain measurement

KW - Pain quality

KW - Psychological assessment

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=78650415128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650415128&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2010.07.031

DO - 10.1016/j.pain.2010.07.031

M3 - Article

C2 - 20851519

AN - SCOPUS:78650415128

VL - 152

SP - 14

EP - 27

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1

ER -